Literature DB >> 26340407

Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Cecilia J Proietti1, Franco Izzo1, María Celeste Díaz Flaqué1, Rosalía Cordo Russo1, Leandro Venturutti1, María Florencia Mercogliano1, Mara De Martino1, Viviana Pineda1, Sergio Muñoz1, Pablo Guzmán1, Juan C Roa1, Roxana Schillaci1, Patricia V Elizalde1.   

Abstract

Accumulated findings have demonstrated the presence of bidirectional interactions between progesterone receptor (PR) and the ErbB family of receptor tyrosine kinases signaling pathways in breast cancer. We previously revealed signal transducer and activator of transcription 3 (Stat3) as a nodal convergence point between said signaling pathways proving that Stat3 is activated by one of the ErbBs' ligands, heregulin (HRG)β1 via ErbB2 and through the co-option of PR as a signaling molecule. Here, we found that HRGβ1 induced Stat3 recruitment to the promoters of the progestin-regulated cell cycle modulators Bcl-XL and p21(CIP1) and also stimulated Stat3 binding to the mouse mammary tumor virus promoter, which carries consensus progesterone response elements. Interestingly, HRGβ1-activated Stat3 displayed differential functions on PR activity depending on the promoter bound. Indeed, Stat3 was required for PR binding in bcl-X, p21(CIP1), and c-myc promoters while exerting a PR coactivator function on the mouse mammary tumor virus promoter. Stat3 also proved to be necessary for HRGβ1-induced in vivo tumor growth. Our results endow Stat3 a novel function as a coregulator of HRGβ1-activated PR to promote breast cancer growth. These findings underscore the importance of understanding the complex interactions between PR and other regulatory factors, such as Stat3, that contribute to determine the context-dependent transcriptional actions of PR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26340407      PMCID: PMC5414679          DOI: 10.1210/me.2015-1170

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  71 in total

1.  Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer.

Authors:  Cecilia J Proietti; Wendy Béguelin; María Celeste Díaz Flaqué; Florencia Cayrol; Martín A Rivas; Mercedes Tkach; Eduardo H Charreau; Roxana Schillaci; Patricia V Elizalde
Journal:  Steroids       Date:  2010-12-22       Impact factor: 2.668

2.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

3.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

4.  Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling.

Authors:  T Yamamoto; T Matsuda; A Junicho; H Kishi; F Saatcioglu; A Muraguchi
Journal:  FEBS Lett       Date:  2000-12-08       Impact factor: 4.124

5.  Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.

Authors:  Andrea R Daniel; Carol A Lange
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

6.  Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.

Authors:  Chengfeng Yang; Eric A Klein; Richard K Assoian; Marcelo G Kazanietz
Journal:  Biochem J       Date:  2008-02-15       Impact factor: 3.857

7.  Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity.

Authors:  J K Richer; C A Lange; N G Manning; G Owen; R Powell; K B Horwitz
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

8.  Nucleosome-driven transcription factor binding and gene regulation.

Authors:  Cecilia Ballaré; Giancarlo Castellano; Laura Gaveglia; Sonja Althammer; Juan González-Vallinas; Eduardo Eyras; Francois Le Dily; Roser Zaurin; Daniel Soronellas; Guillermo P Vicent; Miguel Beato
Journal:  Mol Cell       Date:  2012-11-21       Impact factor: 17.970

9.  STAT3 is required for the gp130-mediated full activation of the c-myc gene.

Authors:  N Kiuchi; K Nakajima; M Ichiba; T Fukada; M Narimatsu; K Mizuno; M Hibi; T Hirano
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

10.  Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Authors:  A R Daniel; A L Gaviglio; T P Knutson; J H Ostrander; A B D'Assoro; P Ravindranathan; Y Peng; G V Raj; D Yee; C A Lange
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

View more
  6 in total

1.  MORC4 Promotes Chemoresistance of Luminal A/B Breast Cancer via STAT3-Mediated MID2 Upregulation.

Authors:  Jing Luo; Shiyan Zeng; Chao Tian
Journal:  Onco Targets Ther       Date:  2020-07-12       Impact factor: 4.147

2.  Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.

Authors:  Joseph F Peevey; Brandon-Luke L Seagle; Kruti P Maniar; J Julie Kim
Journal:  Oncotarget       Date:  2017-06-27

3.  Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.

Authors:  Todd P Knutson; Thu H Truong; Shihong Ma; Nicholas J Brady; Megan E Sullivan; Ganesh Raj; Kathryn L Schwertfeger; Carol A Lange
Journal:  J Hematol Oncol       Date:  2017-04-17       Impact factor: 17.388

Review 4.  Astrocytoma: A Hormone-Sensitive Tumor?

Authors:  Alex Hirtz; Fabien Rech; Hélène Dubois-Pot-Schneider; Hélène Dumond
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

5.  Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Authors:  Patricia V Elizalde; Rosalía I Cordo Russo; Santiago Madera; Franco Izzo; María F Chervo; Agustina Dupont; Violeta A Chiauzzi; Sofia Bruni; Ezequiel Petrillo; Sharon S Merin; Mara De Martino; Diego Montero; Claudio Levit; Gabriel Lebersztein; Fabiana Anfuso; Agustina Roldán Deamicis; María F Mercogliano; Cecilia J Proietti; Roxana Schillaci
Journal:  Cell Death Dis       Date:  2022-05-09       Impact factor: 9.685

6.  Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy.

Authors:  Mara De Martino; Mercedes Tkach; Sofía Bruni; Darío Rocha; María F Mercogliano; Mauro E Cenciarini; María F Chervo; Cecilia J Proietti; Florent Dingli; Damarys Loew; Elmer A Fernández; Patricia V Elizalde; Eliane Piaggio; Roxana Schillaci
Journal:  Oncoimmunology       Date:  2020-01-29       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.